Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, the company knows the need for treatment options is urgent - that is why its global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow.

Company profile
Ticker
TVTX
Exchange
Website
CEO
Eric Dube
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Desert Gateway, Inc., Retrophin, Inc.
SEC CIK
Corporate docs
Subsidiaries
Travere Therapeutics Pharmaceutical, Inc. • Travere Therapeutics Ireland Limited • Travere Therapeutics Switzerland GmbH • Travere Therapeutics Research Ltd • Travere Therapeutics US Holdings, LLC • Kyalin Biosciences, Inc. • Manchester Pharmaceuticals LLC ...
IRS number
262383102
TVTX stock data
Analyst ratings and price targets
Current price
Average target
$30.67
Low target
$22.00
High target
$42.00
Piper Sandler
Maintains
$42.00
Stifel
Initiated
$22.00
Wells Fargo
Initiated
$28.00
Latest filings (excl ownership)
8-K
Travere Therapeutics Provides Corporate Update and 2023 Outlook
9 Jan 23
10-Q
2022 Q3
Quarterly report
27 Oct 22
8-K
Travere Therapeutics Reports Third Quarter 2022 Financial Results
27 Oct 22
8-K
Other Events
13 Oct 22
8-K
Other Events
22 Aug 22
S-8
Registration of securities for employees
18 Aug 22
8-K/A
Departure of Directors or Certain Officers
17 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Travere Therapeutics Reports Second Quarter 2022 Financial Results
4 Aug 22
8-K
Other Events
16 May 22
Transcripts
TVTX
Earnings call transcript
2022 Q3
28 Oct 22
TVTX
Earnings call transcript
2022 Q2
7 Aug 22
TVTX
Earnings call transcript
2022 Q1
8 May 22
TVTX
Earnings call transcript
2021 Q4
25 Feb 22
TVTX
Earnings call transcript
2021 Q3
29 Oct 21
TVTX
Earnings call transcript
2021 Q2
31 Jul 21
TVTX
Earnings call transcript
2021 Q1
9 May 21
TVTX
Earnings call transcript
2020 Q4
2 Mar 21
TVTX
Earnings call transcript
2020 Q3
8 Nov 20
TVTX
Earnings call transcript
2020 Q2
2 Aug 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 151.34 mm | 151.34 mm | 151.34 mm | 151.34 mm | 151.34 mm | 151.34 mm |
Cash burn (monthly) | 9.47 mm | (no burn) | 23.17 mm | 22.00 mm | 13.18 mm | 13.21 mm |
Cash used (since last report) | 36.95 mm | n/a | 90.38 mm | 85.81 mm | 51.39 mm | 51.53 mm |
Cash remaining | 114.38 mm | n/a | 60.96 mm | 65.53 mm | 99.95 mm | 99.81 mm |
Runway (months of cash) | 12.1 | n/a | 2.6 | 3.0 | 7.6 | 7.6 |
Institutional ownership, Q3 2022
13F holders | Current |
---|---|
Total holders | 171 |
Opened positions | 24 |
Closed positions | 24 |
Increased positions | 62 |
Reduced positions | 54 |
13F shares | Current |
---|---|
Total value | 1.71 bn |
Total shares | 68.97 mm |
Total puts | 99.10 k |
Total calls | 338.20 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 5.84 mm | $143.80 mm |
Ra Capital Management | 4.92 mm | $121.30 mm |
BLK Blackrock | 4.56 mm | $112.48 mm |
Deep Track Capital | 4.00 mm | $98.56 mm |
JHG Janus Henderson | 3.91 mm | $96.40 mm |
Vanguard | 3.38 mm | $83.32 mm |
MCQEF Macquarie | 3.31 mm | $81.59 mm |
Baker Bros. Advisors | 3.30 mm | $81.31 mm |
GS Goldman Sachs | 2.55 mm | $62.93 mm |
Adage Capital Partners GP, L.L.C. | 2.35 mm | $57.90 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
25 Jan 23 | Sandra Calvin | Common Stock | Sell | Dispose S | No | Yes | 21.63 | 192 | 4.15 k | 34,836 |
24 Jan 23 | Rote William E. | Common Stock | Sell | Dispose S | No | Yes | 21.5 | 2,062 | 44.33 k | 42,376 |
24 Jan 23 | Reed Elizabeth E | Common Stock | Sell | Dispose S | No | Yes | 21.5 | 2,062 | 44.33 k | 39,776 |
24 Jan 23 | Eric M Dube | Common Stock | Sell | Dispose S | No | Yes | 21.5 | 6,442 | 138.50 k | 147,846 |
24 Jan 23 | Christopher R. Cline | Common Stock | Sell | Dispose S | No | No | 21.9044 | 852 | 18.66 k | 32,871 |
24 Jan 23 | Sandra Calvin | Common Stock | Sell | Dispose S | No | No | 21.9044 | 905 | 19.82 k | 35,028 |
News
Piper Sandler Maintains Overweight on Travere Therapeutics, Raises Price Target to $42
11 Jan 23
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
14 Dec 22
Stifel Initiates Coverage On Travere Therapeutics with Hold Rating, Announces Price Target of $22
14 Dec 22
Stocks That Hit 52-Week Lows On Monday
12 Dec 22
4 Analysts Have This to Say About Travere Therapeutics
5 Dec 22
Press releases
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jan 23
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
3 Jan 23
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14 Dec 22
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Nov 22
Travere Therapeutics to Present at Upcoming Investor Conferences
9 Nov 22